Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
116 participants
OBSERVATIONAL
2018-07-11
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sleep Apnea, Obesity and Pregnancy
NCT02029859
The Effect of OSA on Pregnancy and Fetal Outcomes
NCT06391138
Predictors of De-novo Development of Obstructive Sleep Apnea in Pregnancy
NCT02917876
Obstructive Sleep Apnea in Pregnancy
NCT02383706
Sleep Disordered Breathing, Obesity and Pregnancy Study (SOAP)
NCT02086448
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aim 2: To test the hypothesis that obesity is associated with sympathetic activation, while OSA magnifies this abnormality during pregnancy. Study team will use the state-of-the-art technique of microneurography to measure resting sympathetic activity (primary endpoint) and sympathetic neural responses to physiological stimulations (e.g., mental stress, exercise and upright posture) during early (\<12 weeks) and late (30-34 weeks) pregnancy, and postpartum (6-10 weeks post) in obese women with and without OSA and non-obese women without OSA.
Aim 3: To test the hypothesis that corin content is greater in obese than nonobese women during pregnancy, and it is the greatest in obese pregnant women with OSA. Venous blood samples will be taken in women enrolled in Aim 2 study for measurements of serum corin content (primary endpoint) and pregnancy-specific angiogenic factors such as soluble fms-like tyrosine kinase 1, placental growth factor, and soluble endoglin. The relationships between maternal corin content, pregnancy-specific angiogenic factors, sympathetic activity, and BP will be explored.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
obese women with normal gestational weight gain
obese women (body mass index ≥30 kg/m2) with weight gain 5-9 kg
No interventions assigned to this group
obese women excessive gestational weight gain
obese women (body mass index ≥30 kg/m2) with weight gain \>9 kg
No interventions assigned to this group
non-obese women with normal gestational weight gain
non-obese women (body mass index 18.5-24.9 kg/m2) with weight gain 11.5-16 kg
No interventions assigned to this group
non-obese women with excessive weight gain
non-obese women (body mass index 18.5-24.9 kg/m2) with weight gain \>16 kg
No interventions assigned to this group
obese women with OSA
obese women (body mass index ≥30 kg/m2) with Obstructive Sleep Apnea (OSA) (Apnea and Hypopnea Index (AHI) ≥5 events/hr
No interventions assigned to this group
obese women without OSA
obese women (body mass index ≥30 kg/m2) without Obstructive Sleep Apnea (OSA) (AHI \<5 events/ hr)
No interventions assigned to this group
non-obese women without OSA
non-obese women without OSA (AHI \<5 events/ hr)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No restriction with respect to race and socioeconomic status
* Women with a prior history of complicated pregnancy (i.e., gestational hypertension, preeclampsia, HELLP syndrome, gestational diabetes, preterm birth, intrauterine growth restriction, etc.) will be allowed to participate.
* Obese women with previously diagnosed OSA will be allowed to participate if they are not currently on any recognized treatments such as Continuous Positive Airway Pressure (CPAP), oral appliances or nasal expiratory positive airway pressure.
* Those who have had surgery for OSA in the past will be excluded.
* Women taking low-dose aspirin will be allowed to participate in this project.
Exclusion Criteria
* Known major fetal chromosomal or anatomical abnormalities;
* Recurrent miscarriage (three or more);
* Chronic essential hypertension (systolic BP \>140 mmHg and/or diastolic BP \>90 mmHg);
* Any evidence of cardiovascular and pulmonary diseases by history or by physical examination;
* Kidney disease (serum creatinine \>1.5 mg/dL);
* Coagulation disorders;
* Diabetes mellitus (fasting glucose ≥126 mg/dL or 2-hour oral glucose tolerance test glucose level ≥200 mg/dL) or other systemic illness;
* Any evidence of neurological disease;
* Psychiatric disease or psychological disorders;
* History of drug or alcohol abuse within the last 2 years; and
* Given the effects of exercise training on sympathetic neural control, endurance-trained athletes will be excluded. As this project focuses on sleep apnea in pregnancy, Women with other significant sleep disorders such as restless legs syndrome by Rest Leg Syndrome Diagnostic Index and insomnia by the Insomnia Severity Index or Pittsburgh Sleep Quality Index will be excluded; In addition, women who report taking a sleeping aid \>1 time per month will be excluded.
18 Years
64 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Texas Southwestern Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qi Fu
Professor-Internal Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qi Fu, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
UT Southwestern Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute for Exercise and Environment Medicine (IEEM) at Texas Health Presbyterian Hospital
Dallas, Texas, United States
University of Texas Southwestern Medical Center Dallas
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STU 062018-089
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.